Lowering Events in Non-proliferative Retinopathy in Scotland

PHASE4CompletedINTERVENTIONAL
Enrollment

1,151

Participants

Timeline

Start Date

July 23, 2018

Primary Completion Date

November 17, 2023

Study Completion Date

February 16, 2024

Conditions
Diabetic Retinopathy
Interventions
DRUG

Fenofibrate 145 mg

One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)

DRUG

Placebo Oral Tablet

One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)

Trial Locations (16)

Unknown

NHS Grampian, Aberdeen

NHS Lanarkshire, Airdrie

NHS Ayrshire and Arran, Ayr

NHS Dumfries and Galloway, Dumfries

NHS Tayside, Dundee

NHS Fife, Dunfermline

NHS Lanarkshire, East Kilbride

NHS Lothian, Edinburgh

NHS Greater Glasgow and Clyde, Glasgow

NHS Highland, Inverness

NHS Ayrshire and Arran, Kilmarnock

NHS Fife, Kirkcaldy

NHS Forth Valley, Larbert

NHS Borders, Melrose

NHS Tayside, Perth

NHS Lanarkshire, Wishaw

All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

collaborator

University of Glasgow

OTHER

collaborator

University of Aberdeen

OTHER

collaborator

University of Dundee

OTHER

collaborator

University of Edinburgh

OTHER

collaborator

NHS Scotland Diabetic Retinopathy Screening Collaborative

OTHER

lead

University of Oxford

OTHER

NCT03439345 - Lowering Events in Non-proliferative Retinopathy in Scotland | Biotech Hunter | Biotech Hunter